Dasiglucagon
A ready-to-use glucagon analogue for emergency rescue from severe low blood sugar
Dasiglucagon is a glucagon analogue that stays stable in solution, so it can be injected straight from an autoinjector in an emergency. Approved as Zegalogue in 2021 for severe hypoglycaemia; Drugs@FDA now lists both presentations as discontinued.
Last FDA label of a product discontinued in the US (not a current US recommendation): 0.6 mg, Single dose, Subcutaneous Details ↓
Recommended Dosing
Last FDA label of a product discontinued in the US (not a current US recommendation)
From the last US prescribing information of a product discontinued in the US (see the regulatory status on this page). It records what that label said while the product was sold there; it is not a current US recommendation. Other doses studied, if any, are in the full dosing data below.
Work out syringe units → · New to syringes? · All dosing data ↓
What is it?
Severe hypoglycaemia, blood sugar low enough that a person needs help to recover, is the most feared acute complication of insulin treatment. The standard rescue was glucagon, which releases glucose stored in the liver, but native glucagon is unstable in liquid, so older emergency kits had to be mixed from a powder in the moment.
Dasiglucagon was engineered with amino-acid changes that keep it stable in solution, so the 0.6 mg dose comes ready to inject. In phase 3 trials in adults and children with type 1 diabetes, it raised blood sugar within a median of about 10 minutes, as fast as reconstituted glucagon; with the autoinjector, 88% recovered within 15 minutes against none on placebo. It was approved as Zegalogue in March 2021; as of October 2, 2026, Drugs@FDA lists both Zegalogue presentations as discontinued.
The safety work for a rescue drug is mostly about rare use done well. Three weekly doses produced no antidrug antibodies in 112 people, and intravenous doses up to 1.5 mg did not prolong QTc to a level of regulatory concern. In the placebo-controlled adult trials, the label reports nausea in 57% and vomiting in 25% within 12 hours, the familiar cost of glucagon.
Because it is stable in liquid, researchers have tried it at microdoses. An 80 to 120 µg dose prevented insulin-induced lows faster than oral carbohydrate, and in a two-week free-living study pump users who used an 80 µg pen instead of snacks recovered 44% faster and ate 11% less carbohydrate. After gastric bypass, a single small dose with a meal cut time in hypoglycaemia by about 70 minutes in 10 patients. None of these doses or uses is approved.
Beyond diabetes rescue, it has been studied as a continuous infusion in congenital hyperinsulinism, a rare condition in infants and children. Continuous high glucagon exposure has a known cost: one infant on prolonged infusion developed necrolytic migratory erythema, the rash seen with glucagon-secreting tumours, which resolved after stopping. That use is not approved either.
Mechanism of Action
Dasiglucagon is a glucagon analogue that stays stable in liquid; it raises blood sugar by making the liver release stored glucose.
Glucagon receptor
Activates hepatic glucagon receptors, releasing glucose from stored glycogen (Zegalogue label 12.1).
Stable in solution
Amino-acid substitutions keep it from aggregating in liquid, so no reconstitution is needed before injection.
Short-lived
Half-life about 30 minutes after subcutaneous injection (label 12.3).
Published Research
The studies behind dasiglucagon, read from their PubMed abstracts.
Phase 3 in adults with type 1 diabetes
In 170 adults during insulin-induced hypoglycaemia, 0.6 mg dasiglucagon restored blood sugar in a median 10 minutes against 40 on placebo and 12 on reconstituted glucagon; 99% recovered within 15 minutes. Nausea and vomiting were the commonest effects.
Phase 3 in children aged 6 to 17
In 42 children and adolescents, median recovery was 10 minutes on dasiglucagon against 30 on placebo, and every child on dasiglucagon or glucagon recovered within 20 minutes, against 2 of 11 on placebo.
Pooled safety and efficacy
Across placebo-controlled trials there were no serious adverse events, withdrawals or deaths; treatment-related nausea affected 56.5% and vomiting 24.6%. Median recovery was 10 minutes against 12 on glucagon and 40 on placebo.
Congenital hyperinsulinism, children
In 32 children aged 0.6 to 10.9 years, adding a dasiglucagon infusion did not significantly cut finger-prick-detected hypoglycaemia (the primary end point), but a post hoc analysis found 43% less hypoglycaemia on continuous glucose monitoring.
Congenital hyperinsulinism, infants
In 12 infants dependent on intravenous glucose, dasiglucagon cut the glucose infusion rate needed to keep blood sugar normal to 4.3 mg/kg/min against 9.5 on placebo over 48 hours.
Low blood sugar after gastric bypass
In 24 people with post-bariatric hypoglycaemia, four weeks of self-injected 120 µg doses cut time below 3.0 mmol/L by 54% against placebo, and corrected 97.3% of episodes within 15 minutes against 29.1%.
Phase 3 with the autoinjector
In 45 adults with type 1 diabetes given 0.6 mg or placebo by autoinjector after induced hypoglycaemia, median recovery took 10 minutes against 35; 88% recovered within 15 minutes on dasiglucagon and none on placebo, whether injected in the buttock or the arm.
No antibodies after repeat doses
In 112 people with type 1 diabetes given three weekly doses of dasiglucagon 0.6 mg or recombinant glucagon 1 mg, no one developed treatment-induced antidrug antibodies over 15 weeks.
Heart rhythm (QTc) in volunteers
In 60 healthy volunteers given intravenous doses up to 1.5 mg or the approved 0.6 mg under the skin, the modelled QTc change stayed below the 10 ms threshold of regulatory concern; nausea and vomiting were the commonest effects.
Low dose to prevent a low
In a phase 2 crossover in type 1 diabetes, 80 or 120 µg of dasiglucagon raised glucose by 20 mg/dL in a median 15 minutes against 30 for oral carbohydrate, and hypoglycaemia followed in 4 to 5 participants against 10.
Low-dose pen in daily life
In 24 pump users with type 1 diabetes over two 2-week periods, using an 80 µg pen dose instead of carbohydrate for impending or mild lows gave 44% faster recovery and 11% lower daily carbohydrate intake, without a significant change in time in range. This is not an approved use.
After gastric bypass: crossover
In 10 people with low blood sugar after gastric bypass, a single 80 or 200 µg dose with a test meal raised the lowest glucose from 3.0 to 3.9 or 4.5 mmol/L and cut time in hypoglycaemia by about 70 minutes.
A skin reaction on long infusion
Case report: a newborn with congenital hyperinsulinism on prolonged continuous dasiglucagon developed necrolytic migratory erythema, a rash linked to high glucagon, with malnutrition and zinc and amino-acid deficiency; it improved after the drug was stopped.
A stable analogue against the old kit
58 people with type 1 diabetes received 0.1 to 1.0 mg of dasiglucagon or 0.5 or 1.0 mg of GlucaGen during insulin-induced hypoglycaemia. Both raised glucose above 70 mg/dL within 6 to 10 minutes; dasiglucagon peaked at about 35 minutes with a half-life near half an hour and lasted longer.
Dosing Data
Zegalogue is a single-dose rescue injection for severe hypoglycaemia, given by a caregiver into the abdomen, buttocks, thigh or outer arm.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
Listed as discontinued in the US (see Legal status below); the label on file is described here.
The approved product, as its label describes it:
- Zegalogue (dasiglucagon injection): 0.6 mg/0.6 mL single-dose autoinjector. 0.6 mg/0.6 mL single-dose prefilled syringe. Forms the label lists: single-dose autoinjectors and single-dose prefilled syringes.
Source: Zegalogue (dasiglucagon injection) label, section 3 (DailyMed version 3, effective January 1, 2023).
Mixing a vial: a worked example
Nothing to mix: the label gives Zegalogue (dasiglucagon injection) as single-dose autoinjectors and single-dose prefilled syringes, ready to use.
Source: Zegalogue (dasiglucagon injection) label, sections 2, 3 and 16 (DailyMed version 3, effective January 1, 2023).
Storage before and after mixing
Before mixing or first use: “Store ZEGALOGUE in a refrigerator, 2°C to 8°C (36°F to 46°F).” “ZEGALOGUE can be kept at room temperature between 20°C to 25°C (68°F to 77°F) for up to 12 months.” “Do not return the product to the refrigerator after storing at room temperature.”
After mixing or first use: the label sentences we read say nothing separate about this.
Source: Zegalogue (dasiglucagon injection) label, sections 16 and 2 (DailyMed version 3, effective January 1, 2023).
How it is taken
As the approved label gives it: Subcutaneous (Single dose; Label: severe hypoglycaemia, adults and children aged 6 and older).
Source: Last FDA label of a product discontinued in the US (not a current US recommendation): the route and frequency of each row in Dosing Data below.
What to expect, and when
How long it stays in the body: a half-life of about 30 minutes after an injection under the skin. After about five half-lives almost none is left.
How long the doses were given: Label: severe hypoglycaemia, adults and children aged 6 and older: If no response after 15 minutes, a second dose from a new device may be given.
When effects appear: unknown; no source on this page gives a time to effect for Dasiglucagon. Results reported in the studies are under Published Research.
Source: half-life: Zegalogue prescribing information, section 12.3 (DailyMed set 14704879-872c-4967-8779-04a3bbdfb4e6, effective January 1, 2023; read October 2, 2026); Last FDA label of a product discontinued in the US (not a current US recommendation), the duration of each row in Dosing Data below.
Side effects, and when to stop or get help
From the Side Effects section: Nausea and vomiting, the commonest effects, as with glucagon; Skin and gastrointestinal effects with continuous infusion in children. Full list and cautions ↓
When to stop or get help: unknown; the label's warnings summary we read gives no rule for stopping Dasiglucagon. Treat a severe or unexpected reaction as a reason to stop and see a doctor.
Source: the Side Effects section below (“From the studies above”).
Interactions
- beta-blockers: transient increase in pulse and blood pressure
- indomethacin: dasiglucagon may fail to raise blood glucose or may even produce hypoglycaemia
- warfarin: may increase warfarin's anticoagulant effect
Every peptide's record, with its source: the interaction matrix.
Source: Novo Nordisk. ZEGALOGUE (dasiglucagon) injection, US prescribing information, section 7. DailyMed version effective January 1, 2023, read October 5, 2026.
Checking what you bought
Unknown: no published independent test of Dasiglucagon products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder; it checks the measured mass against Dasiglucagon's expected mass, 3,381.6 Da, from this entry's molecular data. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: Discontinued (Approved in the US as Zegalogue (dasiglucagon), NDA 214231, on March 22, 2021, for severe hypoglycaemia in people with diabetes aged 6 and older). Sport: Not on the 2026 List.
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
From the studies above.
Contraindications & Cautions
Warnings from the Zegalogue label (DailyMed, effective January 1, 2023).
Legal Status
Dasiglucagon was approved in the US as Zegalogue; Drugs@FDA now lists it as discontinued.
Frequently Asked Questions
?What is dasiglucagon?
A glucagon analogue that stays stable in liquid, approved as Zegalogue in 2021 for severe hypoglycaemia in people with diabetes aged 6 and older.
?How fast does it work?
In phase 3 trials it raised blood sugar in a median of about 10 minutes, similar to reconstituted glucagon and much faster than placebo.
?Is Zegalogue still available?
As of October 2, 2026, Drugs@FDA lists both Zegalogue presentations as discontinued, although a label remains on DailyMed.
?Is dasiglucagon the same as glucagon?
No. It is an analogue with amino-acid changes that keep it stable in liquid, so it needs no mixing; it acts on the same receptor and works about as fast.
?What side effects should caregivers expect?
Nausea and vomiting are common: in the adult placebo-controlled trials, 57% had nausea and 25% vomiting within 12 hours. Turn the person on their side and give carbohydrate once they can swallow.
?Can it be used in small doses to prevent lows?
Studies have tested 80 to 200 µg doses for that and for low blood sugar after gastric bypass, with encouraging early results, but no low-dose product or use is approved.
References
- [fda] US FDA, Drugs@FDA (openFDA): ZEGALOGUE and ZEGALOGUE (AUTOINJECTOR) (dasiglucagon), NDA 214231, original approval March 22, 2021; marketing status Discontinued. Read October 2, 2026.
- [fda-pi] FDA. Zegalogue (dasiglucagon) injection US prescribing information (DailyMed set 14704879-872c-4967-8779-04a3bbdfb4e6, version 3, effective January 1, 2023). Read October 2, 2026.
- [clinical-trial] Pieber TR, et al. "Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial." Diabetes Care, 2021;44(6):1361-1367. PMID: 35239971.
- [clinical-trial] Battelino T, et al. "Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial." Pediatr Diabetes, 2021;22(5):734-741. PMID: 33934456.
- [pubmed] Heller S, et al. "Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetes." Diabetes Obes Metab, 2023;25(5):1351-1360. PMID: 36692230.
- [clinical-trial] Thornton PS, et al. "Dasiglucagon for the Treatment of Congenital Hyperinsulinism: A Randomized Phase 3 Trial in Infants and Children." J Clin Endocrinol Metab, 2024;109(4):1071-1079. PMID: 37930757.
- [clinical-trial] De Leon DD, et al. "Dasiglucagon in Children With Congenital Hyperinsulinism Up to 1 Year of Age: Results From a Randomized Clinical Trial." J Clin Endocrinol Metab, 2025;110(8):e2674-e2681. PMID: 39584500.
- [clinical-trial] Nielsen CK, et al. "Dasiglucagon Treatment for Postprandial Hypoglycemia After Gastric Bypass: A Randomized, Double-Blind, Placebo-Controlled Trial." Diabetes Care, 2023;46(12):2208-2217. PMID: 37819999.
- [clinical-trial] Bailey TS, et al. "Dasiglucagon, a next-generation glucagon analogue, for treatment of severe hypoglycaemia via an autoinjector device: Results of a phase 3, randomized, double-blind trial." Diabetes Obes Metab, 2021;23(10):2329-2335. PMID: 34169625.
- [clinical-trial] Pieber TR, et al. "Immunogenicity of the Novel Glucagon Analogue Dasiglucagon: Results of a Dedicated Immunogenicity Trial in Type 1 Diabetes." Diabetes Technol Ther, 2021;23(11):773-776. PMID: 34252289.
- [clinical-trial] Tehranchi R, et al. "Dasiglucagon Effects on QTc in Healthy Volunteers: A Randomized, Placebo-Controlled, Dose-Escalation, Double-Blind Study." Curr Ther Res Clin Exp, 2022;96:100668. PMID: 35464292.
- [clinical-trial] Laugesen C, et al. "Low-Dose Dasiglucagon Versus Oral Glucose for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes: A Phase 2, Randomized, Three-Arm Crossover Study." Diabetes Care, 2022;45(6):1391-1399. PMID: 35475907.
- [clinical-trial] Laugesen C, et al. "Pen-administered low-dose dasiglucagon vs usual care for prevention and treatment of non-severe hypoglycaemia in people with type 1 diabetes during free-living conditions: a Phase II, randomised, open-label, two-period crossover trial." Diabetologia, 2023;66(7):1208-1217. PMID: 37037948.
- [clinical-trial] Nielsen CK, et al. "Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial." Diabetes Care, 2022;45(6):1476-1481. PMID: 35320361.
- [pubmed] Weschle L, et al. "Necrolytic migratory erythema following prolonged continuous subcutaneous dasiglucagon administration: a rare dermatologic adverse event." Endocrinol Diabetes Metab Case Rep, 2025;2025(2). PMID: 40300042.
- [fda-pi] Zegalogue (dasiglucagon) injection US prescribing information (Novo Nordisk; DailyMed set 14704879, version 3, effective January 1, 2023), sections 2.1, 2.2, 6.1 and 12.3; read through openFDA October 6, 2026.
- [pubmed] Hövelmann U, et al. "Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog." Diabetes Care, 2018;41(3):531-537. PMID: 29273578.
Sources & Citations
Studies were read from their PubMed abstracts; the label from DailyMed (set 14704879, effective January 1, 2023) through openFDA, read October 6, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.